Article 17 Mar 2026 REGENXBIO, Inc. v. Sarepta Therapeutics: Recombinant DNA Molecule Patent-Eligibility Under 35 U.S.C. § 101 United States IP
Article 28 Jul 2025 Eye Therapies, LLC. v. Slayback Pharma, LLC: How Prosecution History Can Alter Phrase Interpretation United States IP
Article 13 Mar 2025 US Synthetic Corp. v. International Trade Commission: Safeguarding Structure And Property Limitations In Composition-of-Matter Claims United States Healthcare